Main Menu About Corcept Leading the discovery and development of drugs that modulate the effects of cortisol Cortisol dysregulation plays an important role in a variety of endocrine, metabolic, oncologic, psychiatric, and ophthalmologic diseases. Corcept leads the field in the research and development of selective glucocorticoid receptor (GR) antagonists, having discovered more than 500 proprietary molecules since being founded in 1998. Corcept is committed to improving patient lives through the discovery and development of drugs that address serious unmet medical needs related to excess cortisol activity. To support this mission, Corcept collaborates with numerous basic scientists and clinical researchers to find better ways to improve patient lives. Through our collaborations with researchers around the world, more than 30 studies are underway to investigate the potential benefits GR antagonists may have in the treatment of serious and life-threatening diseases driven by cortisol dysregulation. Corcept Pipeline LEARN MORE About Executive Team Board of Directors Educational Grants Contact Us Product Korlym for Cushing Syndrome Medical Information Request Patients Research & Pipeline Cortisol Modulation Cortisol Modulation Therapeutic Platform Pipeline and Clinical Trials Publications Investigator-Initiated Studies Compassionate Use Investors Investors Overview Press Releases Events Corporate Governance Analyst Coverage Stock Information SEC Filings Careers Benefits Testimonials Current Opportunities © 2021 Corcept Privacy Policy Terms of Use Site Map We use cookies to evaluate and improve your user experience on our website, to analyze our website traffic, and for advertising purposes. To learn more about how we use cookies, and how to change your cookie settings, please visit our Privacy Policy. By continuing to use our site you consent to our use of cookies. ACKNOWLEDGED